TXG · 10x Genomics, Inc.
$48.06
+2.15% last session
End-of-day data · updated 2026-07-25
Market cap
$6B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
223.9
Dividend yield
—
Beta
2.04
Avg volume
3M
Employees
1K
2D change
-3.72%
5D change
7.06%
10D change
1.14%
30D change
29.50%
60D change
87.94%
MTD change
18.49%
YTD change
183.69%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TXG
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-17
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$37.00
-23.0% vs priceCitigroup
Neutral$45.00
-6.4% vs priceBarclays
Overweight$40.00
-16.8% vs priceJP Morgan
Neutral$20.00
-58.4% vs priceBank of America
Neutral$30.00
-37.6% vs priceUBS
Neutral$20.00
-58.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-17 | Leerink Partners | Maintains | Market Perform | $23.00 → $40.00 |
| 2026-07-14 | Canaccord Genuity | Maintains | Buy | $32.00 → $50.00 |
| 2026-07-09 | Morgan Stanley | Maintains | Equal-Weight | $22.00 → $37.00 |
| 2026-07-08 | Citigroup | Maintains | Neutral | $24.00 → $45.00 |
| 2026-07-01 | Piper Sandler | Maintains | Neutral | $20.00 → $42.00 |
| 2026-06-24 | Barclays | Maintains | Overweight | $30.00 → $40.00 |
| 2026-05-12 | Morgan Stanley | Maintains | Equal-Weight | $20.00 → $22.00 |
| 2026-05-12 | JP Morgan | Maintains | Neutral | $17.00 → $20.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 72 — overbought territory; the recent run-up may be due for a pause.
- Price vs 50-day MA: Trading 43.4% above the 50-day MA ($33.51).
- Price vs 200-day MA: Trading 115.5% above the 200-day MA ($22.30).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.21) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($48.06).
TXG Price Chart
Loading chart for TXG…
Fundamentals
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
More in Health Information Services
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.